Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Helps Bayer’s Eylea Sales To Sparkle

Strong Quarter For German Major

Executive Summary

Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.

You may also be interested in...



Takeda Expands Hemophilia Play In India But Hemlibra Has Made Inroads

Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary

Bayer Back In Radiopharmaceuticals Ring With Noria Buy

Although Bayer's radiopharmaceutical for prostate cancer Xofigo has proved a commercial disappointment, the Leverkusen-headquartered firm is keen to advance its pipeline of targeted alpha therapies, snapping up Noria and its subsidiary PSMA Therapeutics.

Bayer's Finerenone Stacks Up More CV Benefit Data Ahead Of Potential Approval

The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel